<unk> , sold under the brand name Pepaxto, is an anticancer medication used to treat multiple myeloma. The most common adverse reactions include fatigue, nausea, diarrhea, pyrexia and respiratory tract infection.<unk>  is a peptidase enhanced cytotoxic (PEnC) that exerts a targeted delivery of<unk>  in cells with high expression of aminopeptidases, such as aminopeptidase N, which has been described as over-expressed in human malignancies. Aminopeptidase N plays a functional role in malignant angiogenesis.<unk>  was approved for medical use in the United States in February 2021.
Melphalan flufenamide
Normustine
Ifosfamide
Fluorouracil
Carmustine
GemOx
Topotecan
Etoposide